AKBA vs PH: Which Is the Better Buy in 2026?
Last updated August 2026
Short answer
PH is the larger of the two ($123.13B market cap): the incumbent the market prices for continued execution (28.63x forward earnings, beta 1.11). AKBA is the smaller challenger ($354.10M), priced similarly on forward earnings (-6.95x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
AKBA vs PH: the tie-breaker metrics
Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | AKBA | PH | What it tells you |
|---|---|---|---|
| Market cap | $354.10M | $123.13B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | -6.95 | 28.63 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 0.23 | 1.11 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 17% of range | 83% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 12.94 | 8.43 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how AKBA and PH affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AKBA and PH share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AKBA and PH exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Akebia Therapeutics (AKBA) do?
Akebia Therapeutics is a commercial-stage biopharmaceutical company built around treating kidney disease. Its flagship product is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor approved in the US to treat anemia caused by chronic kidney disease (CKD) in adults on dialysis. Vafseo launched in the US in January 2025 and is the company's primary growth engine. Akebia's second marketed product is Auryxia (ferric citrate), used to control serum phosphorus in dialysis patients and to treat iron deficiency anemia in non-dialysis CKD patients.
What does Parker Hannifin (PH) do?
Parker Hannifin makes motion and control technologies: hydraulics, pneumatics, filtration, sealing and electromechanical systems used across industrial machinery and aerospace.
AKBA vs PH: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- AKBA drivers: Vafseo launch trajectory; Dialysis channel and reimbursement.
- PH drivers: Aerospace is now a major earnings engine; Aftermarket and replacement demand.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The dominant risk is concentration: Akebia is a small-cap biopharma whose fortunes rest heavily on a single product launch, so any slowdown in Vafseo uptake, reimbursement, or competition from injectable ESAs and rival HIF-PH inhibitors could quickly reset the thesis. For PH, industrial demand is cyclical and tracks capital spending, manufacturing output and construction.
AKBA or PH: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick AKBA if you believe its drivers more; PH if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AKBA and PH guides.
AKBA vs PH: the full fundamentals
AKBA. Figures are approximate and tied to the asOf date; verify live numbers before acting. For a small commercial-stage biopharma, traditional earnings multiples are of limited use because the company is in an investment phase and profitability depends on how fast Vafseo scales relative to spending. Investors typically watch product revenue trends, patient and prescriber counts, cash runway, and pipeline readouts more than a single P/E figure.
PH. Parker is a diversified industrial whose story in recent years has been margin expansion and the aerospace mix shift rather than rapid revenue growth. Verify current segment margins and leverage.
Headline figures (approximate, Jul 2026): AKBA shows revenue (ttm) roughly $230 to $240 million (trailing twelve months as of late 2025), q1 2026 total net product revenue about $52 million (Vafseo ~$15.8M, Auryxia ~$36.2M), vafseo growth patients treated up roughly 60% versus the prior quarter; net revenue growing sequentially, auryxia trend declining, with generic competition expanding in 2026 and revenue guided lower year over year; PH shows business model Motion and control components across industrial and aerospace, key mix shift Aerospace substantially larger after the Meggitt acquisition, revenue quality Large aftermarket and replacement component, balance sheet Carries acquisition debt; verify current leverage.
The bottom line: AKBA vs PH
AKBA and PH are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined AKBA and PH exposure against your real portfolio. It is not an investment adviser.
Wondering how AKBA or PH fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Akebia Therapeutics with AI
Connect the broker you already use and ask Walnut's AI how AKBA fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between AKBA and PH?
+
Akebia Therapeutics is a commercial-stage biopharmaceutical company built around treating kidney disease. Parker Hannifin makes motion and control technologies: hydraulics, pneumatics, filtration, sealing and electromechanical systems used across industrial machinery and aerospace. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is AKBA or PH the better stock?
+
Neither is universally better. PH is the larger incumbent; AKBA is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, AKBA or PH?
+
On forward P/E (as of August 2026), AKBA trades at -6.95x and PH at 28.63x, so AKBA is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both AKBA and PH?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of AKBA vs PH?
+
AKBA: The dominant risk is concentration: Akebia is a small-cap biopharma whose fortunes rest heavily on a single product launch, so any slowdown in Vafseo uptake, reimbursement, or competition from injectable ESAs and rival HIF-PH inhibitors could quickly reset the thesis. Auryxia revenue is declining as generics expand, pressuring total sales during the Vafseo ramp. As a company at this scale, Akebia may need to fund commercialization and clinical trials from cash, debt, or equity, and any capital raise could dilute shareholders or add leverage. Pipeline programs in FSGS and other rare kidney diseases face clinical, regulatory, and timing uncertainty, with key readouts still years away. The stock can be volatile on launch metrics, quarterly revenue, trial news, and financing announcements. PH: Industrial demand is cyclical and tracks capital spending, manufacturing output and construction. The Meggitt acquisition added meaningful debt, so deleveraging progress matters. Aerospace revenue depends on air traffic and defence budgets. As a global manufacturer, Parker is exposed to currency, tariffs and supply-chain disruption.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell AKBA or PH; figures are approximate and dated (as of August 2026). Verify current data before investing.